Navigation Links
Transgenomic, Inc. Reports Second Quarter 2007 Results
Date:8/19/2007

end of the fiscal year."

Mr. Tuttle continued, "Our Pharmaceutical Research Services group performed work for six pharmaceutical companies so far this year, and we signed several new contracts with these and other new partners which will result in continued growth for this division. We are also in the process of increasing resources in our clinical molecular diagnostics lab to further drive growth similar to what we have been experiencing for this business over the last few quarters. Finally, we expect to realize the full impact of the ongoing consolidations and other cost reduction by the fourth quarter of the year. This is a very exciting time for the company as we enjoy the results of our refocusing on strong financial performance in our traditional mutation discovery tools business and substantial growth in our diagnostics laboratory business and Pharmaceutical Research Services business."

Earnings Call

Company management will discuss second quarter 2007 financial results via teleconference on Tuesday, August 14, 2007 at 5:00 p.m. Eastern Time. To access the call via telephone, dial 800-896-8445 or 785-830-1916. The company will also host a live broadcast of the call over the Internet. To listen to the webcast, investors should log on to the company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions provided. An archived recording of the conference call will be available and can be accessed via the web using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern Time on Tuesday, August 28, 2007. Simply dial 800-839-9881 or 402-220-3100 from any telephone.

About Transgenomic: A decade of discovery 1997 - 2007

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genet
'/>"/>

SOURCE Transgenomic, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... that they have expanded their colony counter product line ... InCount and ImpressCount. These affordable colony counters that ... food microbiology and pharmaceutical manufacturing. , The previously released ... bright white enclosure with jet black accents represent the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Possible mold re-infestation ... so, according to a report from eagletribune.com posted May 14, ... In case the result is positive, My Cleaning Products offered ... harmful chemical ingredients. , It was said in the Eagle ... in the campus sparked after a first-grade classroom was ...
(Date:5/21/2013)... Clinovo's new “CDISC Standards: Theory and Application” ... June 11th, 2013. The TechTrainings are technical hands-on classes ... step in their professional career. The class will be ... online. , Taught by Sy Truong, President at Meta-Xceed ... Theory and Application” class will give an overview of ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3Clinovo Launches TechTrainings on CDISC Standards 2
... the University of Helsinki, Finland, has succeeded in producing ... is reduced to a nano-scale (one nanometre being one ... undergo substantial changes. Unlike in bulk materials, in nanoparticles ... the number of atoms inside the material, which, among ...
... Corporation (Amex: ETC ) ("ETC" or ... will be exhibiting at the upcoming APWCA 2009 ... (APWCA) 2009 National Conference will be held April ... Philadelphia, Center City. The APWCA provides cutting-edge education ...
... Portfolio LAKE FOREST, Ill., March 16 ... equity firm focused exclusively on the healthcare ... CorePharma LLC ("CorePharma") has completed the acquisition ... Leucovorin Calcium tablets are the generic equivalent ...
Cached Biology Technology:Paper electrified by copper particles 2Environmental Tectonics Corporation Announces Participation at APWCA National Conference 2Environmental Tectonics Corporation Announces Participation at APWCA National Conference 3RoundTable Healthcare Partners Facilitates Product Acquisition for CorePharma 2
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... of Illinois at Chicago College of Medicine will study gender ... its main energy source -- and how changes in fat ... $2 million, 4-year grant from the National Heart, Lung and ... uses fuel for energy. These changes may play a major ... in men and women, says E. Douglas Lewandowski, director of ...
(Date:5/21/2013)... -- Over the past few decades, scientists have developed ... balloons and metallic stents. While generally effective, each of ... effects. , A new study from MIT analyzes the ... benefits of angioplasty balloons and drug-releasing stents, but may ... is inflated in the artery for only a brief ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... have identified a subtype of ovarian cancer able to build ... especially susceptible to "anti-angiogenic" drugs that block blood vessel formation. ... PloS ONE , the investigators estimate that the subtype may ... common cancer of the surface of the ovaries. The ...
... AUSTIN, Texas Chemists at The University of Texas at ... inside the double helix of a DNA sequence that it can ... itself, much longer than any other molecule reported. It,s an ... go after rogue DNA directly. Such drugs would be revolutionary in ...
... , The Springer journal Analytical and Bioanalytical Chemistry ... as the recipients of its Best Paper Award 2011. Rmpp ... in ABC on mass spectrometry imaging. The award, accompanied by ... scientists and to stimulate their research careers. The ABC Best ...
Cached Biology News:New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 2New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs 3New molecule can tangle up DNA for more than 2 weeks 2ABC Best Paper Award 2011 goes to Andreas Römpp and Sabine Guenther 2
Phospho-C/EBPbeta (Thr235) Antibody...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
COMING SOON: Anti-Mouse C5a Receptor (CD88), Clone 10/92 Monoclonal Antibody...
... ( Abpromise for all tested applications). ... PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding to ... melanogaster) SARA. Conserved sequence unique to ... 9372 Swiss Protein ...
Biology Products: